Bioenergetics and Molecular Biotechnologies (IBIOM), CNR Institute of Biomembranes, 70125 Bari, Italy.
Interdisciplinary Department of Medicine (DIM), University of Bari Aldo Moro, 70124 Bari, Italy.
Biomolecules. 2023 May 18;13(5):858. doi: 10.3390/biom13050858.
The availability of drugs capable of blocking the replication of microorganisms has been one of the greatest triumphs in the history of medicine, but the emergence of an ever-increasing number of resistant strains poses a serious problem for the treatment of infectious diseases. The search for new potential ligands for proteins involved in the life cycle of pathogens is, therefore, an extremely important research field today. In this work, we have considered the HIV-1 protease, one of the main targets for AIDS therapy. Several drugs are used today in clinical practice whose mechanism of action is based on the inhibition of this enzyme, but after years of use, even these molecules are beginning to be interested by resistance phenomena. We used a simple artificial intelligence system for the initial screening of a data set of potential ligands. These results were validated by docking and molecular dynamics, leading to the identification of a potential new ligand of the enzyme which does not belong to any known class of HIV-1 protease inhibitors. The computational protocol used in this work is simple and does not require large computational power. Furthermore, the availability of a large number of structural information on viral proteins and the presence of numerous experimental data on their ligands, with which it is possible to compare the results obtained with computational methods, make this research field the ideal terrain for the application of these new computational techniques.
药物的出现能够阻止微生物的复制,这是医学史上的重大成就之一,但越来越多的耐药菌株的出现给传染病的治疗带来了严重的问题。因此,寻找新的潜在配体来针对病原体生命周期中的蛋白是当今极其重要的研究领域。在这项工作中,我们研究了 HIV-1 蛋白酶,它是艾滋病治疗的主要靶点之一。目前在临床实践中使用了几种药物,它们的作用机制基于抑制这种酶,但经过多年的使用,即使这些分子也开始出现耐药现象。我们使用了一个简单的人工智能系统对潜在配体数据集进行初步筛选。这些结果通过对接和分子动力学得到了验证,从而确定了一种新型的 HIV-1 蛋白酶抑制剂酶的潜在配体,它不属于任何已知的 HIV-1 蛋白酶抑制剂类别。本工作中使用的计算方案简单,不需要大量的计算能力。此外,大量病毒蛋白的结构信息和它们配体的大量实验数据的可用性,使得这些结果可以与计算方法的结果进行比较,这使得这个研究领域成为应用这些新计算技术的理想领域。